LOGIN  |  REGISTER

List of Biotechnology Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 457.36
-5.77 -1.25
1.11M
253.72M
US$ 116.040B
US$ 722.80
-0.87 -0.12
583,734
103.28M
US$ 74.650B
US$ 465.34
-7.95 -1.68
508,700
132.11M
US$ 61.480B
US$ 915.97
-5.83 -0.63
98,999
61.57M
US$ 56.400B
US$ 205.04
-1.74 -0.84
1.16M
213.27M
US$ 43.730B
US$ 96.00
-0.73 -0.75
1.49M
240.46M
US$ 23.080B
US$ 484.10
3.14 0.65
428,196
43.06M
US$ 20.850B
US$ 32.02
0.34 1.07
1.41M
615.99M
US$ 19.720B
US$ 100.46
-1.04 -1.02
1.04M
196.32M
US$ 19.720B
US$ 184.71
0.00 0.00
0
97.68M
US$ 18.040B
US$ 39.15
-0.45 -1.14
3.22M
427.25M
US$ 16.730B
US$ 154.22
2.26 1.49
340,276
99.71M
US$ 15.380B
US$ 78.48
0.79 1.02
2.06M
193.32M
US$ 15.170B
US$ 21.18
0.48 2.32
4.03M
695.49M
US$ 14.730B
US$ 74.76
0.61 0.82
1.51M
192.71M
US$ 14.410B
US$ 131.87
0.00 0.00
0
106.24M
US$ 14.010B
US$ 18.81
0.44 2.40
2.44M
744.44M
US$ 14.000B
US$ 586.21
6.32 1.09
197,711
22.71M
US$ 13.310B
US$ 81.81
-0.03 -0.04
1.94M
161.97M
US$ 13.250B
US$ 208.58
8.08 4.03
625,048
61.10M
US$ 12.740B
US$ 44.37
0.36 0.82
1.82M
268.11M
US$ 11.900B
US$ 71.54
-0.04 -0.06
1.05M
150.68M
US$ 10.780B
US$ 30.70
0.37 1.22
1,546
349.00M
US$ 10.710B
US$ 53.82
-0.49 -0.90
2.01M
192.11M
US$ 10.340B
US$ 166.91
-0.19 -0.11
619,448
60.77M
US$ 10.140B
US$ 25.49
0.31 1.23
6.95M
390.73M
US$ 9.960B
US$ 63.54
-0.28 -0.44
929,545
155.81M
US$ 9.900B
US$ 106.91
0.00 0.00
0
84.98M
US$ 9.090B
US$ 84.66
0.99 1.18
719,236
105.19M
US$ 8.910B
US$ 64.66
-0.42 -0.65
2.93M
135.81M
US$ 8.780B
US$ 110.64
-0.29 -0.26
2.19M
77.90M
US$ 8.620B
US$ 129.46
0.00 0.00
0
64.58M
US$ 8.360B
US$ 66.54
1.88 2.91
1.43M
122.26M
US$ 8.140B
US$ 28.32
1.08 3.96
3.53M
282.15M
US$ 7.990B
US$ 148.04
0.23 0.16
194,310
50.41M
US$ 7.460B
US$ 62.95
-1.71 -2.64
3.60M
117.60M
US$ 7.400B
US$ 96.22
0.10 0.10
2.18M
75.85M
US$ 7.300B
US$ 106.86
-0.04 -0.04
269,289
67.27M
US$ 7.190B
US$ 105.70
1.07 1.02
419,050
66.74M
US$ 7.050B
US$ 220.50
-0.48 -0.22
361,525
31.45M
US$ 6.930B
US$ 221.96
4.50 2.07
329,949
29.00M
US$ 6.440B
US$ 39.31
0.15 0.38
2.21M
153.51M
US$ 6.030B
US$ 46.07
-1.63 -3.42
1.34M
130.91M
US$ 6.030B
US$ 58.18
2.19 3.91
2.62M
95.30M
US$ 5.540B
US$ 87.33
1.26 1.46
443,988
62.52M
US$ 5.460B
US$ 151.27
-0.52 -0.34
554,554
34.89M
US$ 5.280B
US$ 27.81
0.06 0.22
1.12M
184.69M
US$ 5.140B
US$ 31.38
-0.23 -0.73
722,208
158.76M
US$ 4.980B
US$ 105.87
5.87 5.87
622,337
46.27M
US$ 4.900B
US$ 29.30
-0.23 -0.78
1.04M
165.12M
US$ 4.840B
US$ 33.18
0.29 0.88
1.15M
145.68M
US$ 4.830B
US$ 20.11
0.39 1.98
1.73M
238.00M
US$ 4.790B
US$ 66.23
0.24 0.36
610,988
71.95M
US$ 4.770B
US$ 189.97
3.82 2.05
461,351
25.01M
US$ 4.750B
US$ 45.20
1.69 3.88
1.03M
102.01M
US$ 4.610B
US$ 54.63
-0.06 -0.11
2.23M
82.32M
US$ 4.500B
US$ 47.42
0.44 0.94
441,237
94.89M
US$ 4.500B
US$ 26.55
0.67 2.59
1.61M
169.18M
US$ 4.490B
US$ 29.56
0.49 1.69
741,020
146.08M
US$ 4.320B
US$ 75.50
0.95 1.27
905,984
54.83M
US$ 4.140B
US$ 35.85
0.33 0.93
2.45M
113.39M
US$ 4.070B
US$ 22.91
0.20 0.88
978,341
175.28M
US$ 4.020B
US$ 68.45
-4.49 -6.16
3.34M
57.82M
US$ 3.960B
US$ 31.16
1.20 4.01
1.54M
122.49M
US$ 3.820B
US$ 47.41
-0.34 -0.71
670,829
79.05M
US$ 3.750B
US$ 188.50
-4.53 -2.35
136,099
19.68M
US$ 3.710B
US$ 71.53
0.54 0.76
148,199
51.39M
US$ 3.680B
US$ 44.73
2.12 4.98
957,824
80.67M
US$ 3.610B
US$ 46.99
0.00 0.00
0
75.35M
US$ 3.540B
US$ 93.79
1.41 1.53
204,843
37.75M
US$ 3.540B
US$ 36.54
0.09 0.25
922,861
96.48M
US$ 3.530B
US$ 81.83
-0.05 -0.06
189,897
42.45M
US$ 3.470B
US$ 44.61
0.32 0.72
519,746
77.28M
US$ 3.450B
US$ 36.01
1.67 4.86
1.75M
87.67M
US$ 3.160B
US$ 35.33
0.48 1.38
1.18M
89.47M
US$ 3.160B
US$ 25.26
-0.37 -1.44
1.84M
123.73M
US$ 3.130B
US$ 32.46
1.16 3.71
1.10M
95.37M
US$ 3.100B
US$ 38.91
-0.29 -0.74
736,954
79.14M
US$ 3.080B
US$ 9.95
0.17 1.74
3.23M
308.53M
US$ 3.070B
US$ 20.11
1.11 5.84
3.04M
146.66M
US$ 2.950B
US$ 20.65
0.56 2.79
1.85M
142.82M
US$ 2.950B
US$ 33.92
0.18 0.53
632,426
87.00M
US$ 2.950B
US$ 28.91
2.17 8.12
3.19M
101.47M
US$ 2.930B
US$ 23.08
-0.02 -0.09
681,399
122.91M
US$ 2.840B
US$ 8.31
-0.06 -0.72
7.19M
341.83M
US$ 2.840B
US$ 52.68
1.96 3.86
1.02M
53.71M
US$ 2.830B
US$ 22.19
0.94 4.42
3.48M
126.53M
US$ 2.810B
US$ 42.61
1.35 3.27
1.64M
63.93M
US$ 2.720B
US$ 17.46
0.33 1.93
6.34M
152.67M
US$ 2.670B
US$ 12.43
0.97 8.46
8.17M
213.05M
US$ 2.650B
US$ 33.51
1.31 4.07
764,221
77.59M
US$ 2.600B
US$ 23.71
0.39 1.67
699,078
105.87M
US$ 2.510B
US$ 22.82
0.98 4.49
3.84M
104.79M
US$ 2.390B
US$ 2.30
0.10 4.55
12.49M
984.97M
US$ 2.270B
US$ 27.64
0.39 1.43
2.68M
80.16M
US$ 2.220B
US$ 14.89
0.00 0.00
0
148.49M
US$ 2.210B
US$ 17.19
0.26 1.54
151,579
128.29M
US$ 2.210B
US$ 19.95
0.20 1.01
1.23M
110.59M
US$ 2.210B
US$ 38.25
1.25 3.38
523,189
57.60M
US$ 2.200B
US$ 31.77
0.00 0.00
50,675
65.90M
US$ 2.090B
US$ 59.98
0.00 0.00
0
34.44M
US$ 2.070B
US$ 40.22
2.34 6.18
265,969
50.53M
US$ 2.030B
US$ 15.31
0.40 2.68
662,651
131.84M
US$ 2.020B
US$ 23.41
0.39 1.69
553,325
85.15M
US$ 1.990B
US$ 32.85
1.23 3.89
1.34M
60.68M
US$ 1.990B
US$ 26.52
0.30 1.14
441,471
74.84M
US$ 1.980B
US$ 29.60
1.79 6.44
667,290
66.45M
US$ 1.970B
US$ 44.71
0.74 1.68
339,657
42.88M
US$ 1.920B
US$ 36.79
-0.60 -1.60
549,000
50.57M
US$ 1.860B
US$ 20.09
0.72 3.72
1.04M
91.71M
US$ 1.840B
US$ 18.02
1.19 7.07
1.35M
101.37M
US$ 1.830B
US$ 27.69
-1.67 -5.69
637,877
64.96M
US$ 1.800B
US$ 31.05
0.09 0.29
662,990
57.12M
US$ 1.770B
US$ 5.71
0.12 2.15
2.97M
307.07M
US$ 1.750B
US$ 13.47
-0.23 -1.68
3.14M
128.23M
US$ 1.730B
US$ 19.74
0.03 0.15
1.05M
86.91M
US$ 1.720B
US$ 7.83
-0.02 -0.25
8.54M
210.54M
US$ 1.650B
US$ 27.42
-0.07 -0.25
1.25M
58.31M
US$ 1.600B
US$ 14.49
0.28 1.97
524,422
109.82M
US$ 1.590B
US$ 4.38
0.32 7.93
13.36M
363.19M
US$ 1.590B
US$ 5.07
0.43 9.27
1.75M
311.60M
US$ 1.580B
US$ 20.80
-0.06 -0.29
324,375
74.77M
US$ 1.560B
US$ 27.74
0.77 2.86
592,588
54.04M
US$ 1.500B
US$ 5.92
0.15 2.60
3.43M
242.97M
US$ 1.440B
US$ 11.88
1.54 14.89
753,276
121.56M
US$ 1.440B
US$ 22.74
-2.74 -10.75
23.65M
62.29M
US$ 1.420B
US$ 8.00
0.17 2.17
1.07M
173.32M
US$ 1.390B
US$ 5.06
0.57 12.69
8.61M
273.92M
US$ 1.390B
US$ 16.72
2.20 15.15
2.65M
82.79M
US$ 1.380B
US$ 5.18
0.71 15.88
19.43M
266.37M
US$ 1.380B
US$ 28.70
0.94 3.39
492,615
47.66M
US$ 1.370B
US$ 30.54
-3.40 -10.02
4.11M
44.90M
US$ 1.370B
US$ 14.50
-0.08 -0.55
1.61M
92.40M
US$ 1.340B
US$ 3.75
0.18 5.04
2.41M
353.82M
US$ 1.330B
US$ 9.90
0.33 3.45
3.73M
134.68M
US$ 1.330B
US$ 24.76
1.80 7.84
617,956
53.05M
US$ 1.310B
US$ 6.37
0.07 1.11
4.87M
203.47M
US$ 1.300B
US$ 18.14
0.83 4.79
721,008
71.41M
US$ 1.300B
US$ 10.96
-0.01 -0.09
2.22M
117.42M
US$ 1.290B
US$ 9.61
0.49 5.37
3.27M
132.69M
US$ 1.280B
US$ 87.41
4.45 5.36
180,647
14.54M
US$ 1.270B
US$ 7.62
0.48 6.72
3.02M
167.18M
US$ 1.270B
US$ 21.40
0.40 1.90
441,905
59.35M
US$ 1.270B
US$ 47.98
0.00 0.00
0
25.69M
US$ 1.230B
US$ 12.43
0.49 4.10
996,864
97.22M
US$ 1.210B
US$ 43.30
-0.46 -1.05
326,483
27.69M
US$ 1.200B
US$ 17.35
1.54 9.74
69,240
68.51M
US$ 1.190B
US$ 22.11
0.41 1.89
918,984
53.37M
US$ 1.180B
US$ 57.69
0.56 0.98
324,698
20.34M
US$ 1.170B
US$ 26.16
-0.39 -1.47
125,399
44.77M
US$ 1.170B
US$ 25.25
-4.71 -15.72
9.96M
45.72M
US$ 1.150B
US$ 5.12
-0.04 -0.78
760,216
225.17M
US$ 1.150B
US$ 24.28
-0.07 -0.29
936,705
46.81M
US$ 1.140B
US$ 19.70
0.71 3.74
77,196
57.81M
US$ 1.140B
US$ 9.76
0.70 7.73
9.14M
115.83M
US$ 1.130B
US$ 17.26
0.40 2.37
568,094
65.12M
US$ 1.120B
US$ 6.86
0.02 0.29
1.30M
162.50M
US$ 1.110B
US$ 11.39
0.41 3.73
1.19M
97.39M
US$ 1.110B
US$ 6.72
-0.01 -0.15
966,928
165.92M
US$ 1.110B
US$ 3.65
0.16 4.58
3.56M
299.34M
US$ 1.090B
US$ 40.00
0.00 0.00
0
27.02M
US$ 1.080B
US$ 15.00
1.64 12.28
7.56M
70.85M
US$ 1.060B
US$ 21.82
0.79 3.76
35,740
48.22M
US$ 1.050B
US$ 14.70
0.03 0.20
493,987
71.14M
US$ 1.050B
US$ 11.98
0.01 0.08
1.24M
87.02M
US$ 1.040B
US$ 18.76
0.60 3.30
362,577
54.78M
US$ 1.030B
US$ 24.35
1.47 6.42
999,401
41.28M
US$ 1.010B
US$ 15.55
0.00 0.00
0
64.53M
US$ 1.000B
US$ 11.13
0.00 0.00
0
89.31M
US$ 994.020M
US$ 16.40
-0.71 -4.15
2.45M
60.15M
US$ 986.460M
US$ 9.97
0.42 4.40
1.64M
98.85M
US$ 985.530M
US$ 34.47
2.38 7.42
394,437
27.71M
US$ 955.160M
US$ 15.35
0.97 6.75
204,327
62.03M
US$ 952.160M
US$ 18.70
-0.19 -1.01
295,150
50.67M
US$ 947.530M
US$ 6.78
0.51 8.13
3.18M
139.13M
US$ 943.300M
US$ 10.48
0.31 3.05
1.56M
88.80M
US$ 930.620M
US$ 9.50
0.00 0.00
0
97.47M
US$ 925.960M
US$ 3.19
-0.10 -3.04
3.84M
283.71M
US$ 905.030M
US$ 9.70
0.23 2.43
2.28M
92.73M
US$ 899.480M
US$ 3.79
0.01 0.26
5.56M
237.07M
US$ 898.500M
US$ 2.22
0.01 0.45
14.34M
396.97M
US$ 881.270M
US$ 27.90
-0.10 -0.36
442,951
31.29M
US$ 872.990M
US$ 47.38
0.17 0.36
308,821
18.15M
US$ 859.950M
US$ 8.34
0.03 0.36
2.18M
102.68M
US$ 856.350M
US$ 4.41
-0.02 -0.45
449,237
192.32M
US$ 848.130M
US$ 10.64
0.32 3.10
2.42M
78.79M
US$ 838.330M
US$ 16.40
1.74 11.87
4.06M
50.55M
US$ 829.020M
US$ 10.53
0.21 2.03
1.35M
78.44M
US$ 825.970M
US$ 1.27
0.00 0.00
8.76M
638.36M
US$ 810.720M
US$ 8.30
0.46 5.87
859,740
97.21M
US$ 806.840M
US$ 12.55
-0.12 -0.95
1.58M
64.22M
US$ 805.960M
US$ 12.49
0.00 0.00
0
63.96M
US$ 798.860M
US$ 9.38
0.68 7.82
354,686
85.14M
US$ 798.610M
US$ 4.18
0.04 0.97
1.62M
191.02M
US$ 798.460M
US$ 10.60
0.54 5.37
2.09M
75.32M
US$ 798.390M
US$ 6.45
0.30 4.88
2.31M
122.00M
US$ 786.900M
US$ 11.03
0.41 3.86
780,076
70.90M
US$ 782.030M
US$ 3.33
-0.09 -2.63
2.46M
231.46M
US$ 770.760M
US$ 7.90
0.26 3.40
27,928
96.33M
US$ 761.010M
US$ 8.81
0.16 1.85
7,967
85.92M
US$ 756.960M
US$ 17.16
0.00 0.00
0
41.89M
US$ 718.830M
US$ 3.85
0.24 6.65
16.77M
180.51M
US$ 694.960M
US$ 8.60
0.48 5.91
433,910
80.49M
US$ 692.210M
US$ 4.08
0.08 2.00
3.67M
169.44M
US$ 691.320M
US$ 4.49
0.21 4.91
3.30M
149.06M
US$ 669.280M
US$ 9.09
0.43 4.97
938,876
72.99M
US$ 663.480M
US$ 8.83
0.39 4.62
1.17M
74.68M
US$ 659.420M
US$ 12.98
0.10 0.78
821,959
50.62M
US$ 657.050M
US$ 11.19
0.49 4.58
518,867
57.14M
US$ 639.400M
US$ 10.58
0.08 0.76
489,605
59.08M
US$ 625.070M
US$ 20.27
2.17 11.99
1.10M
30.47M
US$ 617.630M
US$ 11.16
-0.01 -0.09
697,632
53.83M
US$ 600.740M
US$ 7.83
0.00 0.00
0
76.38M
US$ 598.060M
US$ 3.41
0.00 0.00
0
171.00M
US$ 583.110M
US$ 8.00
0.16 2.04
2.23M
71.36M
US$ 570.880M
US$ 8.16
0.00 0.00
0
69.23M
US$ 564.920M
US$ 3.73
0.44 13.37
22.04M
150.37M
US$ 560.880M
US$ 9.82
0.05 0.51
270,920
56.96M
US$ 559.350M
US$ 5.36
0.25 4.89
4.32M
104.34M
US$ 559.260M
US$ 35.27
0.27 0.77
31,216
15.82M
US$ 557.970M
US$ 8.68
0.00 0.00
0
62.78M
US$ 544.930M
US$ 25.46
3.15 14.12
69,188
21.22M
US$ 540.260M
US$ 3.70
0.19 5.41
2.07M
145.02M
US$ 536.570M
US$ 4.64
0.00 0.00
0
115.27M
US$ 534.850M
US$ 79.47
2.29 2.97
147,648
6.68M
US$ 530.860M
US$ 2.22
-0.01 -0.45
2.20M
233.12M
US$ 517.530M
US$ 1.42
0.02 1.43
5.23M
363.40M
US$ 516.030M
US$ 72.50
-1.56 -2.11
83,808
7.09M
US$ 514.020M
US$ 13.05
0.06 0.46
2.34M
38.87M
US$ 507.250M
US$ 8.66
-0.06 -0.69
703,226
56.30M
US$ 487.560M
US$ 8.76
-0.30 -3.31
658,379
54.12M
US$ 474.090M
US$ 5.92
0.73 14.07
1.73M
77.91M
US$ 461.230M
US$ 6.34
0.16 2.59
179,961
71.61M
US$ 454.010M
C$ 5.77
-0.39 -6.33
230,234
78.34M
C$ 452.020M
US$ 16.81
0.31 1.88
209,091
26.82M
US$ 450.840M
US$ 8.63
0.12 1.41
453,535
52.08M
US$ 449.450M
US$ 10.15
0.00 0.00
0
44.21M
US$ 448.730M
US$ 9.21
0.20 2.22
920,445
48.52M
US$ 446.870M
US$ 13.18
0.60 4.77
635,309
33.86M
US$ 446.270M
US$ 3.54
-0.41 -10.38
2.43M
123.88M
US$ 438.540M
US$ 6.69
-0.05 -0.74
524,059
64.57M
US$ 431.970M
US$ 1.59
0.02 1.27
1.98M
265.37M
US$ 421.940M
US$ 1.57
0.09 6.08
10.80M
266.14M
US$ 417.840M
US$ 6.45
0.15 2.38
57,935
63.50M
US$ 409.580M
C$ 8.06
-0.19 -2.30
83,489
50.65M
C$ 408.240M
US$ 14.09
-0.15 -1.05
159,160
28.85M
US$ 406.500M
US$ 6.30
0.60 10.53
585,703
64.47M
US$ 406.160M
US$ 16.79
0.00 0.00
0
24.17M
US$ 405.810M
US$ 2.10
0.11 5.53
2.01M
192.09M
US$ 403.390M
US$ 1.74
0.06 3.57
965,881
230.33M
US$ 400.770M
US$ 4.45
-0.12 -2.63
2.03M
89.35M
US$ 397.610M
US$ 7.71
0.12 1.58
110,709
50.91M
US$ 392.520M
US$ 8.60
0.00 0.00
0
45.44M
US$ 390.780M
US$ 10.16
0.09 0.89
62,714
38.22M
US$ 388.320M
US$ 1.24
0.03 2.48
27.76M
312.32M
US$ 387.280M
US$ 2.28
0.005 0.22
1.12M
169.94M
US$ 386.610M
US$ 31.13
0.13 0.42
24,098
12.38M
US$ 385.390M
US$ 3.65
0.00 0.00
0
104.39M
US$ 381.020M
US$ 7.15
0.00 0.00
0
52.76M
US$ 377.230M
US$ 10.50
1.28 13.88
1.19M
35.86M
US$ 376.530M
US$ 8.05
0.00 0.00
0
46.67M
US$ 375.690M
US$ 3.42
0.08 2.40
1.13M
108.22M
US$ 370.110M
US$ 4.26
0.00 0.00
0
86.32M
US$ 367.720M
US$ 5.31
0.06 1.14
805,767
68.75M
US$ 365.060M
US$ 2.55
0.09 3.66
1.52M
141.55M
US$ 360.950M
US$ 13.38
-0.01 -0.07
239,330
26.97M
US$ 360.860M
US$ 7.14
0.00 0.00
294,223
49.93M
US$ 356.500M
US$ 0.23
0.0025 1.09
1.16M
1.54B
US$ 355.740M
US$ 4.83
0.17 3.65
65,934
72.33M
US$ 349.350M
US$ 4.06
0.18 4.64
138,916
85.26M
US$ 346.160M
US$ 7.84
0.66 9.19
797,896
43.80M
US$ 343.390M
US$ 16.46
0.17 1.04
46,938
20.79M
US$ 342.200M
US$ 3.80
0.55 16.92
439,738
87.44M
US$ 332.270M
US$ 21.16
1.04 5.17
624,210
15.49M
US$ 327.770M
US$ 3.01
0.23 8.27
2.83M
108.35M
US$ 326.130M
US$ 17.95
0.98 5.77
458,026
18.13M
US$ 325.430M
US$ 2.04
0.08 4.08
5.54M
159.13M
US$ 324.630M
US$ 1.44
-0.08 -5.26
1.45M
224.73M
US$ 323.610M
US$ 3.68
0.21 6.05
903,509
85.59M
US$ 314.970M
US$ 5.20
-0.07 -1.33
438,114
59.10M
US$ 307.320M
US$ 5.67
0.00 0.00
0
53.68M
US$ 304.370M
US$ 5.95
0.32 5.68
630,814
49.89M
US$ 296.850M
US$ 4.88
0.01 0.21
987,011
60.16M
US$ 293.580M
US$ 4.00
-0.06 -1.48
2.04M
73.33M
US$ 293.320M
US$ 2.88
0.03 1.05
487,122
100.60M
US$ 289.730M
US$ 5.26
0.24 4.78
1.65M
54.90M
US$ 288.770M
US$ 1.97
0.09 4.79
300,665
143.96M
US$ 283.600M
US$ 1.16
0.07 6.42
2.45M
236.29M
US$ 274.100M
US$ 1.97
0.05 2.60
8.47M
137.04M
US$ 269.970M
US$ 4.32
-0.28 -6.09
612,630
62.26M
US$ 268.960M
US$ 1.80
0.11 6.51
20.63M
149.00M
US$ 268.200M
US$ 5.29
0.10 1.93
405,663
50.39M
US$ 266.560M
US$ 5.00
0.00 0.00
0
53.23M
US$ 266.150M
US$ 7.78
0.21 2.77
76,216
34.15M
US$ 265.690M
US$ 6.87
0.07 1.03
413,897
38.59M
US$ 265.110M
US$ 4.68
-0.18 -3.70
137,354
56.46M
US$ 264.230M
US$ 4.87
0.14 2.96
643,971
54.19M
US$ 263.910M
US$ 1.78
0.08 4.71
96,749
147.19M
US$ 262.000M
US$ 2.07
-0.01 -0.48
553,927
126.31M
US$ 261.460M
US$ 4.58
0.14 3.15
162,195
56.55M
US$ 259.000M
US$ 4.00
0.00 0.00
0
64.56M
US$ 258.240M
US$ 20.56
2.25 12.29
27,941
12.53M
US$ 257.620M
US$ 4.78
-0.10 -2.05
2.98M
53.23M
US$ 254.440M
US$ 10.98
-0.14 -1.26
71,539
23.10M
US$ 253.640M
US$ 3.89
0.21 5.71
238,799
65.02M
US$ 252.930M
US$ 1.75
0.21 13.64
23.49M
142.44M
US$ 249.270M
US$ 2.56
0.06 2.40
4.14M
96.27M
US$ 246.450M
US$ 1.30
0.009 0.70
7.98M
187.27M
US$ 243.260M
US$ 4.85
0.00 0.00
0
50.00M
US$ 242.500M
US$ 4.35
0.12 2.84
611,487
55.60M
US$ 241.860M
US$ 3.09
0.00 0.00
469,207
78.13M
US$ 241.420M
US$ 1.31
0.04 3.15
8.52M
183.36M
US$ 240.200M
US$ 2.43
0.06 2.53
3.02M
97.62M
US$ 237.220M
US$ 17.98
0.27 1.52
184,635
12.82M
US$ 230.500M
US$ 19.53
1.75 9.84
2.22M
11.78M
US$ 230.060M
US$ 1.38
0.05 3.76
9.50M
166.51M
US$ 229.780M
US$ 2.27
0.00 0.00
0
100.95M
US$ 229.160M
US$ 2.12
0.11 5.47
2.45M
105.35M
US$ 223.340M
US$ 2.60
-0.02 -0.76
6.88M
85.17M
US$ 221.440M
US$ 4.47
0.00 0.00
0
48.36M
US$ 216.170M
US$ 5.94
-0.05 -0.83
69,743
36.33M
US$ 215.800M
US$ 1.77
0.08 4.73
396,909
118.82M
US$ 210.310M
US$ 3.60
0.08 2.27
7.20M
55.68M
US$ 200.450M
US$ 6.35
-0.11 -1.70
744,654
31.00M
US$ 196.850M
US$ 6.90
0.31 4.70
564,066
28.41M
US$ 196.030M
US$ 2.97
0.37 14.23
798,022
63.28M
US$ 187.940M
US$ 10.69
0.02 0.19
268,169
17.55M
US$ 187.610M
US$ 1.51
0.07 4.86
2.24M
121.27M
US$ 183.120M
US$ 8.33
-0.18 -2.12
513,073
21.91M
US$ 182.510M
US$ 1.94
0.08 4.30
2.96M
93.47M
US$ 181.330M
US$ 6.90
0.25 3.76
1.03M
26.00M
US$ 179.400M
US$ 0.53
0.03 6.15
38.86M
336.49M
US$ 178.340M
C$ 2.33
-0.07 -2.92
2,600
76.38M
C$ 177.970M
US$ 4.65
0.00 0.00
117,276
38.05M
US$ 176.930M
US$ 1.91
0.01 0.53
2,308
92.18M
US$ 176.060M
US$ 6.75
0.37 5.80
113,464
25.61M
US$ 172.740M
US$ 7.35
-0.08 -1.08
50,818
23.24M
US$ 170.810M
US$ 4.28
0.55 14.75
2.01M
39.50M
US$ 169.060M
US$ 4.52
0.07 1.46
1,135
37.40M
US$ 168.860M
US$ 17.90
0.46 2.64
70,746
9.05M
US$ 162.000M
US$ 3.32
0.22 7.10
1.89M
48.31M
US$ 160.390M
US$ 1.77
0.08 4.73
1.21M
90.32M
US$ 159.870M
US$ 18.23
2.48 15.75
201,591
8.57M
US$ 156.230M
US$ 4.74
-0.11 -2.27
145,158
32.92M
US$ 156.040M
US$ 1.76
-0.04 -2.22
2.40M
88.27M
US$ 155.360M
US$ 2.71
0.02 0.74
5.77M
56.97M
US$ 154.390M
US$ 1.55
-0.07 -4.32
6.26M
97.54M
US$ 151.190M
US$ 1.61
0.04 2.55
231,118
93.54M
US$ 150.600M
US$ 1.23
0.01 0.82
2.18M
120.87M
US$ 148.670M
US$ 2.16
0.03 1.41
1.80M
67.36M
US$ 145.500M
US$ 21.99
0.00 0.00
0
6.60M
US$ 145.130M
US$ 8.33
0.27 3.35
128,724
17.26M
US$ 143.690M
US$ 2.54
-0.11 -4.15
48,835
55.90M
US$ 141.990M
US$ 1.75
0.03 1.74
578,950
80.42M
US$ 140.740M
US$ 6.50
0.33 5.35
446,073
21.49M
US$ 139.680M
US$ 2.02
0.00 0.00
1.92M
68.70M
US$ 138.770M
US$ 6.37
0.56 9.64
217,770
21.74M
US$ 138.480M
US$ 4.06
-0.11 -2.64
559,905
34.01M
US$ 138.080M
US$ 1.09
0.03 2.83
46,901
126.01M
US$ 137.350M
US$ 27.47
-0.38 -1.36
70,716
5.00M
US$ 137.350M
US$ 9.49
0.02 0.21
144,362
14.42M
US$ 136.850M
US$ 1.21
0.07 6.14
4.98M
109.15M
US$ 132.070M
US$ 1.84
0.06 3.37
766,859
71.03M
US$ 130.700M
US$ 3.55
0.23 6.90
1.27M
36.24M
US$ 128.620M
US$ 2.28
0.00 0.00
1.99M
56.34M
US$ 128.460M
C$ 1.54
-0.06 -3.75
475,914
83.41M
C$ 128.450M
US$ 1.10
0.02 1.85
1.90M
115.35M
US$ 126.890M
US$ 6.00
-0.15 -2.44
126,173
20.92M
US$ 125.520M
C$ 0.67
0.02 3.08
137,391
185.51M
C$ 124.290M
US$ 4.65
0.00 0.00
495,292
26.50M
US$ 123.220M
US$ 8.80
0.39 4.64
22,326
13.85M
US$ 121.880M
US$ 5.02
-0.04 -0.79
177,620
24.07M
US$ 120.830M
US$ 1.98
0.05 2.59
197,760
60.57M
US$ 119.930M
US$ 1.59
0.00 0.00
1.76M
75.03M
US$ 119.300M
US$ 1.62
0.04 2.53
6.76M
71.21M
US$ 115.360M
US$ 40.70
0.92 2.31
19,109
2.79M
US$ 113.550M
US$ 2.26
0.00 0.00
0
48.08M
US$ 108.660M
US$ 2.72
0.00 0.00
61,494
39.80M
US$ 108.260M
US$ 27.37
1.51 5.84
8,523
3.94M
US$ 107.840M
US$ 2.09
0.00 0.00
0
50.13M
US$ 104.770M
US$ 0.98
0.07 8.22
2.10M
106.15M
US$ 104.130M
US$ 1.71
0.00 0.00
0
60.18M
US$ 102.910M
US$ 14.20
1.65 13.15
131,653
7.21M
US$ 102.380M
US$ 1.40
0.02 1.45
3.88M
72.25M
US$ 101.150M
US$ 5.91
0.45 8.24
101,868
17.05M
US$ 100.770M
US$ 1.92
0.03 1.59
482,779
51.76M
US$ 99.380M
US$ 0.76
0.02 2.91
1.06M
129.17M
US$ 98.170M
US$ 2.37
0.04 1.72
1,111
41.08M
US$ 97.360M
US$ 90.44
0.28 0.31
47,555
1.07M
US$ 96.770M
US$ 2.11
0.05 2.43
76,074
45.86M
US$ 96.760M
US$ 2.23
0.06 2.76
463,955
42.99M
US$ 95.870M
US$ 1.03
-0.06 -5.50
2.78M
91.88M
US$ 94.640M
US$ 1.97
-0.09 -4.37
51,218
47.13M
US$ 92.850M
US$ 3.78
0.20 5.45
48,308
24.54M
US$ 92.640M
US$ 4.17
0.00 0.00
3.32M
22.08M
US$ 92.070M
US$ 2.06
0.09 4.57
2.76M
44.42M
US$ 91.510M
US$ 0.66
0.06 9.75
23.52M
137.43M
US$ 90.020M
US$ 1.93
0.00 0.00
0
46.15M
US$ 89.070M
US$ 0.37
0.005 1.39
295,188
240.06M
US$ 87.620M
C$ 1.30
0.06 4.84
77,007
66.93M
C$ 87.010M
US$ 2.47
-0.02 -0.80
342,070
35.04M
US$ 86.550M
US$ 1.36
-0.04 -2.86
3.47M
63.26M
US$ 86.030M
US$ 2.75
0.06 2.23
1.37M
31.04M
US$ 85.360M
US$ 0.56
0.02 3.35
8.98M
153.26M
US$ 85.060M
US$ 1.19
0.14 13.33
2.87M
70.70M
US$ 84.130M
US$ 6.10
0.11 1.84
5,324
13.79M
US$ 84.120M
US$ 9.06
0.78 9.42
28,198
9.25M
US$ 83.800M
US$ 0.69
0.04 5.85
4.49M
120.28M
US$ 82.750M
US$ 0.83
0.06 7.42
5.31M
97.99M
US$ 81.140M
US$ 1.31
-0.23 -14.94
45.69M
61.45M
US$ 80.500M
US$ 8.42
0.94 12.57
130,223
9.49M
US$ 79.910M
US$ 1.93
0.03 1.58
5,046
41.12M
US$ 79.360M
US$ 2.68
0.00 0.00
0
28.91M
US$ 77.480M
US$ 11.40
-0.10 -0.87
74,047
6.78M
US$ 77.260M
US$ 1.54
0.16 11.59
383,497
50.02M
US$ 77.030M
US$ 2.51
-0.08 -3.09
43,672
30.49M
US$ 76.530M
US$ 2.41
0.13 5.70
782,258
31.56M
US$ 76.060M
US$ 1.55
0.04 2.65
78,921
49.05M
US$ 76.030M
US$ 1.10
0.08 7.84
3.94M
67.75M
US$ 74.530M
US$ 1.37
0.05 3.79
408,208
54.22M
US$ 74.280M
US$ 3.00
0.00 0.00
0
24.68M
US$ 74.040M
US$ 1.93
0.21 12.21
144,677
37.77M
US$ 72.900M
US$ 2.44
0.03 1.24
600,271
28.10M
US$ 68.560M
US$ 3.39
0.14 4.31
37,652
20.16M
US$ 68.340M
US$ 1.28
-0.01 -0.78
438,484
53.21M
US$ 68.110M
US$ 0.59
-0.0036 -0.61
5.38M
115.06M
US$ 68.000M
US$ 5.69
0.00 0.00
0
11.82M
US$ 67.260M
US$ 1.79
0.02 1.13
2.32M
37.55M
US$ 67.210M
US$ 4.57
-0.12 -2.56
39,362
14.41M
US$ 65.850M
US$ 3.94
-0.02 -0.51
522,189
16.63M
US$ 65.520M
US$ 6.29
-0.93 -12.88
1.31M
10.33M
US$ 64.980M
US$ 6.81
0.77 12.75
989,948
9.42M
US$ 64.150M
US$ 1.82
0.07 4.00
289,985
35.21M
US$ 64.080M
C$ 0.70
0.00 0.00
9,955
90.68M
C$ 63.480M
US$ 3.43
-0.05 -1.44
4,839
18.13M
US$ 62.190M
US$ 2.53
-0.04 -1.56
41,176
24.30M
US$ 61.480M
US$ 5.06
0.50 10.96
23,043
12.02M
US$ 60.820M
US$ 2.22
0.02 0.91
311,090
26.29M
US$ 58.360M
US$ 9.35
0.16 1.74
185,297
6.24M
US$ 58.340M
US$ 1.11
0.09 8.82
1.40M
52.47M
US$ 58.240M
US$ 12.35
1.42 12.99
36,320
4.69M
US$ 57.920M
C$ 0.50
-0.01 -1.96
7,000
113.01M
C$ 56.500M
US$ 1.97
-0.05 -2.33
47,745
28.32M
US$ 55.880M
C$ 1.97
0.02 1.03
10,413
27.42M
C$ 54.020M
US$ 10.09
0.22 2.23
98,132
5.35M
US$ 53.980M
US$ 0.88
0.00 0.00
0
60.97M
US$ 53.650M
US$ 0.87
0.0005 0.06
220,750
60.89M
US$ 53.100M
US$ 1.85
0.20 12.12
4.03M
27.98M
US$ 51.760M
US$ 6.29
0.33 5.54
54,190
7.99M
US$ 50.260M
US$ 1.88
0.12 6.82
690,261
26.59M
US$ 49.990M
US$ 0.85
0.02 2.64
2.96M
58.79M
US$ 49.850M
C$ 0.90
-0.02 -2.17
83,293
54.73M
C$ 49.260M
US$ 9.81
0.00 0.00
0
5.02M
US$ 49.250M
US$ 0.68
0.04 5.74
1.73M
71.95M
US$ 48.780M
US$ 4.97
0.00 0.00
0
9.79M
US$ 48.660M
US$ 0.99
0.07 7.85
1.56M
48.54M
US$ 48.050M
US$ 0.88
0.03 3.16
716,533
54.72M
US$ 48.040M
C$ 0.15
0.00 0.00
100,919
328.69M
C$ 47.660M
US$ 5.21
-0.04 -0.76
47,183
9.05M
US$ 47.150M
US$ 1.14
0.00 0.00
0
41.10M
US$ 46.850M
US$ 1.36
0.04 3.03
241,951
34.38M
US$ 46.760M
US$ 1.27
0.00 0.00
0
36.59M
US$ 46.470M
US$ 3.28
0.12 3.80
60,532
14.13M
US$ 46.350M
US$ 2.73
0.00 0.00
0
16.84M
US$ 45.970M
US$ 0.53
0.01 2.71
2.61M
87.31M
US$ 45.930M
US$ 1.74
0.00 0.00
0
26.31M
US$ 45.780M
US$ 6.25
0.01 0.16
15,440
7.32M
US$ 45.750M
US$ 2.09
0.18 9.42
662,267
21.87M
US$ 45.710M
C$ 0.07
-0.005 -7.14
575,795
701.73M
C$ 45.610M
US$ 1.45
0.00 0.00
81,211
31.20M
US$ 45.240M
US$ 1.20
0.08 7.14
636,874
37.03M
US$ 44.440M
US$ 5.29
0.19 3.73
66,042
8.34M
US$ 44.120M
US$ 1.86
-0.03 -1.59
18,786
23.43M
US$ 43.580M
US$ 12.73
0.70 5.82
41,022
3.39M
US$ 43.150M
US$ 6.74
1.18 21.22
350,667
6.37M
US$ 42.930M
US$ 3.77
0.23 6.50
36,514
11.18M
US$ 42.150M
US$ 0.09
0.001 1.11
30,000
442.60M
US$ 40.280M
US$ 3.10
0.00 0.00
0
12.59M
US$ 39.030M
US$ 0.74
0.04 4.96
962,325
52.50M
US$ 38.900M
US$ 1.21
-0.01 -0.82
200,896
32.06M
US$ 38.790M
US$ 10.00
0.01 0.10
60,861
3.82M
US$ 38.200M
US$ 10.00
0.00 0.00
338
3.81M
US$ 38.100M
US$ 4.34
0.00 0.00
0
8.65M
US$ 37.540M
US$ 1.20
-0.16 -11.76
20,409
31.24M
US$ 37.490M
US$ 3.47
-0.01 -0.29
9,345
10.66M
US$ 36.990M
US$ 1.39
0.01 0.72
197,459
26.29M
US$ 36.540M
C$ 0.22
0.00 0.00
0
165.94M
C$ 36.510M
US$ 22.89
0.75 3.39
115,268
1.59M
US$ 36.400M
US$ 1.00
0.06 6.12
263,871
36.19M
US$ 36.190M
C$ 0.13
-0.01 -7.41
9,008
287.34M
C$ 35.920M
US$ 1.20
-0.03 -2.44
534,900
29.70M
US$ 35.640M
US$ 2.04
0.00 0.00
105,481
17.34M
US$ 35.370M
US$ 5.22
-0.01 -0.19
18,036
6.74M
US$ 35.180M
US$ 1.33
0.00 0.00
0
26.20M
US$ 34.850M
US$ 0.95
0.05 5.04
202,816
36.65M
US$ 34.820M
US$ 2.63
0.01 0.38
54,477
12.86M
US$ 33.820M
C$ 0.24
0.00 0.00
32,373
140.26M
C$ 33.660M
US$ 8.25
0.13 1.60
39,183
4.05M
US$ 33.410M
US$ 0.23
0.02 8.90
22.22M
144.30M
US$ 33.190M
US$ 1.42
0.00 0.00
0
23.18M
US$ 32.920M
C$ 0.63
0.03 5.00
19,000
51.84M
C$ 32.660M
C$ 0.43
0.00 0.00
0
74.76M
C$ 32.150M
US$ 14.75
0.90 6.50
4,802
2.14M
US$ 31.550M
US$ 0.55
0.00 0.00
0
55.22M
US$ 30.370M
US$ 3.26
-0.16 -4.68
11,543
9.25M
US$ 30.150M
US$ 0.33
0.00 0.00
0
90.38M
US$ 29.740M
US$ 0.72
-0.02 -2.57
30,481
40.83M
US$ 29.440M
US$ 1.30
0.26 24.90
8.18M
22.49M
US$ 29.210M
US$ 9.13
0.54 6.29
96,964
3.18M
US$ 29.030M
US$ 0.31
0.004 1.32
441,285
92.87M
US$ 28.420M
US$ 1.65
0.05 3.12
2,000
17.17M
US$ 28.330M
US$ 0.67
0.01 1.52
39,588
42.24M
US$ 28.300M
US$ 0.45
0.04 9.81
89.79M
60.06M
US$ 27.030M
US$ 2.10
0.03 1.45
11,430
12.78M
US$ 26.840M
US$ 3.94
-0.01 -0.25
262,907
6.76M
US$ 26.630M
US$ 3.74
0.41 12.31
36,430
6.99M
US$ 26.140M
US$ 0.63
0.00 0.00
0
41.21M
US$ 25.840M
US$ 1.12
0.01 0.90
234,368
22.23M
US$ 24.900M
US$ 1.10
0.02 1.85
216,867
22.39M
US$ 24.630M
US$ 5.32
0.00 0.00
0
4.57M
US$ 24.310M
US$ 1.79
0.04 2.29
171,209
13.48M
US$ 24.130M
US$ 11.27
2.41 27.20
181,004
2.08M
US$ 23.440M
US$ 1.38
0.00 0.00
666,966
16.85M
US$ 23.250M
US$ 1.25
0.11 9.65
531,060
18.47M
US$ 23.090M
US$ 12.24
-0.40 -3.16
75,807
1.88M
US$ 23.010M
US$ 4.27
0.08 1.91
35,699
5.38M
US$ 22.970M
US$ 2.24
0.11 5.16
62,739
10.19M
US$ 22.830M
US$ 13.38
0.13 0.98
393,447
1.67M
US$ 22.340M
US$ 1.22
0.11 9.91
443,589
18.00M
US$ 21.960M
US$ 0.37
0.00 0.00
0
59.25M
US$ 21.630M
C$ 0.16
0.00 0.00
5,600
132.87M
C$ 21.260M
US$ 0.44
0.02 5.47
1.42M
48.05M
US$ 21.140M
US$ 1.78
0.03 1.71
832
11.73M
US$ 20.880M
US$ 2.36
0.00 0.00
0
8.62M
US$ 20.340M
US$ 38.11
1.44 3.93
150,412
505,798
US$ 19.280M
US$ 1.07
-0.01 -0.93
98,967
18.06M
US$ 19.230M
US$ 2.36
0.25 11.85
646,088
7.99M
US$ 18.860M
US$ 1.19
-0.01 -0.83
101,613
15.51M
US$ 18.460M
US$ 1.42
0.15 11.81
690,350
12.94M
US$ 18.370M
US$ 13.60
0.00 0.00
0
1.32M
US$ 17.950M
US$ 2.03
0.11 5.73
20,658
8.82M
US$ 17.900M
US$ 1.35
0.10 8.00
192,580
12.93M
US$ 17.460M
US$ 3.10
0.01 0.32
13,186
5.55M
US$ 17.200M
US$ 3.42
0.15 4.59
716,957
4.93M
US$ 16.860M
US$ 1.16
0.07 6.42
204,833
14.52M
US$ 16.840M
US$ 1.63
0.08 5.16
491,289
10.09M
US$ 16.450M
US$ 7.63
0.27 3.67
14,829
2.15M
US$ 16.400M
US$ 3.80
0.11 2.98
11,534
4.24M
US$ 16.110M
US$ 0.26
0.005 1.96
2.49M
61.29M
US$ 15.940M
US$ 18.91
1.08 6.06
20,232
838,977
US$ 15.870M
US$ 1.47
0.05 3.52
111,717
10.61M
US$ 15.600M
US$ 4.27
-0.16 -3.61
4,281
3.65M
US$ 15.590M
C$ 0.06
0.00 0.00
0
258.84M
C$ 15.530M
US$ 3.90
0.05 1.17
8,227
3.94M
US$ 15.350M
US$ 0.27
0.004 1.50
14.56M
56.64M
US$ 15.350M
C$ 0.20
0.00 0.00
0
76.57M
C$ 15.310M
US$ 2.47
-0.02 -0.80
126,643
6.16M
US$ 15.220M
US$ 0.98
0.04 4.04
26,522
15.49M
US$ 15.150M
US$ 14.46
7.37 103.96
37.70M
1.04M
US$ 15.040M
US$ 0.05
0.00 0.00
0
265.05M
US$ 14.550M
US$ 1.35
0.06 4.65
443,610
10.76M
US$ 14.530M
C$ 0.03
0.005 25.00
521,833
570.65M
C$ 14.270M
US$ 1.04
-0.005 -0.48
34,675
13.78M
US$ 14.260M
US$ 3.26
0.04 1.15
15,069
4.35M
US$ 14.170M
C$ 0.08
-0.01 -11.76
56,811
181.05M
C$ 13.580M
US$ 1.15
-0.15 -11.54
2.23M
11.70M
US$ 13.450M
US$ 10.56
1.86 21.38
27,728
1.26M
US$ 13.310M
US$ 0.63
-0.0035 -0.55
405,947
19.85M
US$ 12.570M
US$ 1.70
-0.02 -1.16
28,238
7.34M
US$ 12.480M
US$ 0.37
-0.0007 -0.19
454,182
33.29M
US$ 12.450M
US$ 4.00
0.05 1.27
42,049
3.07M
US$ 12.280M
US$ 0.34
0.00 0.00
557,740
35.74M
US$ 12.150M
US$ 2.52
0.10 4.13
53,265
4.81M
US$ 12.120M
US$ 1.60
0.01 0.63
95,920
7.54M
US$ 12.060M
US$ 0.22
0.00 0.00
0
55.66M
US$ 11.990M
US$ 0.92
0.08 8.88
87,969
12.85M
US$ 11.820M
US$ 0.38
-0.02 -4.17
840,036
29.71M
US$ 11.410M
C$ 0.13
0.005 4.17
40,400
91.02M
C$ 11.380M
US$ 1.54
0.04 2.67
53,234
7.17M
US$ 11.040M
US$ 1.56
0.01 0.65
1.33M
6.95M
US$ 10.840M
US$ 1.31
0.16 13.91
104,038
7.85M
US$ 10.280M
US$ 5.31
4.75 849.91
27,819
1.92M
US$ 10.200M
US$ 3.17
0.42 15.16
110,547
3.13M
US$ 9.910M
C$ 0.07
0.00 0.00
1,910
151.90M
C$ 9.870M
US$ 1.11
0.03 2.78
32,174
8.88M
US$ 9.860M
C$ 0.09
0.00 0.00
40,504
108.62M
C$ 9.780M
US$ 0.20
0.00 0.00
0
47.31M
US$ 9.320M
US$ 1.40
0.03 2.19
57,110
6.35M
US$ 8.890M
US$ 1.30
0.00 0.00
0
6.83M
US$ 8.880M
US$ 0.75
-0.07 -8.22
145,035
11.64M
US$ 8.710M
US$ 2.72
0.00 0.00
0
3.18M
US$ 8.650M
US$ 1.16
-0.01 -0.85
1.79M
7.44M
US$ 8.630M
US$ 1.32
0.13 10.92
93,665
6.45M
US$ 8.510M
C$ 0.16
0.02 10.34
20,100
52.95M
C$ 8.470M
US$ 4.43
0.19 4.48
26,270
1.91M
US$ 8.460M
US$ 1.82
0.07 4.00
35,379
4.63M
US$ 8.430M
US$ 8.56
0.00 0.00
0
973,291
US$ 8.330M
US$ 0.36
0.00 0.00
0
23.14M
US$ 8.210M
US$ 0.24
0.04 20.94
5.50M
33.74M
US$ 8.170M
US$ 2.15
0.09 4.37
20,860
3.80M
US$ 8.170M
US$ 0.99
0.07 7.24
950.07M
8.21M
US$ 8.140M
US$ 1.19
0.41 51.67
260.77M
6.80M
US$ 8.090M
US$ 3.59
0.03 0.84
26,805
2.23M
US$ 8.010M
US$ 4.50
0.31 7.40
51,163
1.77M
US$ 7.960M
US$ 8.64
0.23 2.73
3,259
916,968
US$ 7.920M
US$ 2.15
0.05 2.38
53,517
3.68M
US$ 7.910M
US$ 0.14
0.00 0.00
0
55.37M
US$ 7.900M
US$ 0.33
0.01 3.46
400,209
23.99M
US$ 7.820M
US$ 0.85
0.06 8.19
343,442
9.03M
US$ 7.670M
US$ 0.02
0.00 0.00
85,000
332.96M
US$ 7.330M
US$ 3.48
0.20 6.10
34,303
2.09M
US$ 7.270M
US$ 0.08
0.0026 3.36
162,000
88.99M
US$ 7.120M
US$ 1.06
0.03 2.91
179,546
6.31M
US$ 6.690M
US$ 0.60
0.00 0.00
2,518
11.03M
US$ 6.620M
US$ 1.70
0.17 11.11
102,860
3.81M
US$ 6.480M
C$ 0.02
0.005 50.00
760,100
432.32M
C$ 6.480M
US$ 1.13
0.06 5.61
345,845
5.48M
US$ 6.190M
US$ 0.58
-0.03 -4.61
4.17M
10.64M
US$ 6.170M
US$ 4.61
0.00 0.00
0
1.33M
US$ 6.120M
US$ 2.84
0.00 0.00
0
2.12M
US$ 6.020M
US$ 0.45
-0.0036 -0.79
89,434
13.32M
US$ 6.020M
US$ 0.20
0.00 0.00
0
30.12M
US$ 5.930M
US$ 1.00
0.05 4.90
196,059
5.92M
US$ 5.920M
US$ 2.54
0.12 4.96
12,128
2.29M
US$ 5.820M
US$ 0.34
-0.003 -0.88
1.04M
17.07M
US$ 5.790M
US$ 2.22
0.01 0.45
188,514
2.58M
US$ 5.730M
US$ 1.46
0.16 12.31
47,804
3.84M
US$ 5.610M
US$ 0.94
0.00 0.00
0
5.97M
US$ 5.580M
US$ 3.04
0.16 5.56
5,905
1.83M
US$ 5.560M
C$ 2.70
-0.15 -5.26
585
2.04M
C$ 5.510M
US$ 3.35
0.52 18.37
2.27M
1.63M
US$ 5.460M
US$ 0.87
0.01 1.22
1.51M
5.86M
US$ 5.100M
C$ 0.03
0.00 0.00
0
166.23M
C$ 4.990M
US$ 0.77
0.02 3.16
35,982
6.41M
US$ 4.960M
US$ 1.63
0.04 2.52
154,093
2.97M
US$ 4.840M
US$ 0.91
0.00 0.00
0
5.17M
US$ 4.700M
US$ 2.95
-0.04 -1.34
37,948
1.56M
US$ 4.600M
US$ 0.34
0.00 0.00
0
13.54M
US$ 4.560M
US$ 1.05
0.00 0.00
0
4.25M
US$ 4.460M
US$ 0.64
0.006 0.95
22,452
6.96M
US$ 4.450M
US$ 2.04
-0.02 -0.97
11,209
2.15M
US$ 4.390M
US$ 0.13
0.02 16.11
19.81M
33.18M
US$ 4.280M
US$ 2.06
0.41 24.85
1.66M
2.02M
US$ 4.160M
US$ 0.98
-0.04 -3.92
83,309
4.23M
US$ 4.150M
US$ 1.10
0.08 7.84
141,596
3.74M
US$ 4.110M
US$ 0.50
0.00 0.00
0
8.21M
US$ 4.110M
US$ 1.20
0.03 2.56
46,793
3.33M
US$ 4.000M
US$ 0.37
-0.0051 -1.37
172,064
10.74M
US$ 3.930M
US$ 0.53
0.00 0.00
0
7.24M
US$ 3.840M
US$ 0.03
0.00 0.00
0
118.11M
US$ 3.800M
US$ 1.34
0.00 0.00
222,555
2.80M
US$ 3.750M
US$ 6.51
-0.15 -2.25
6,694
574,580
US$ 3.740M
US$ 2.14
-0.02 -0.93
15,044
1.75M
US$ 3.740M
US$ 6.11
0.21 3.56
52,293
596,978
US$ 3.650M
US$ 0.85
-0.01 -1.43
52,449
4.17M
US$ 3.550M
US$ 1.08
-0.07 -6.09
40,580
3.19M
US$ 3.450M
US$ 1.68
-0.12 -6.67
134,859
1.93M
US$ 3.240M
US$ 2.00
0.00 0.00
0
1.61M
US$ 3.220M
US$ 5.09
0.18 3.67
12,607
619,523
US$ 3.150M
C$ 0.01
0.00 0.00
0
312.86M
C$ 3.130M
C$ 0.03
0.00 0.00
23,549
121.27M
C$ 3.030M
C$ 0.08
0.00 0.00
1,000
34.26M
C$ 2.740M
US$ 0.62
-0.07 -9.88
63.94M
4.34M
US$ 2.690M
US$ 2.52
-0.49 -16.28
299,940
1.03M
US$ 2.600M
C$ 0.12
0.00 0.00
19,500
21.15M
C$ 2.540M
US$ 0.56
0.00 0.00
0
4.52M
US$ 2.530M
US$ 0.02
0.00 0.00
0
124.38M
US$ 2.490M
US$ 0.76
0.0005 0.07
1,606
3.18M
US$ 2.420M
US$ 0.25
0.00 0.00
0
9.66M
US$ 2.390M
C$ 0.03
0.00 0.00
0
75.74M
C$ 2.270M
US$ 0.39
0.00 0.00
0
5.23M
US$ 2.040M
US$ 0.06
0.0084 16.28
92,282
33.71M
US$ 2.020M
US$ 0.05
-0.009 -15.79
186,861
41.85M
US$ 2.010M
US$ 0.40
0.09 28.48
111
4.62M
US$ 1.830M
US$ 0.02
0.00 0.00
0
75.46M
US$ 1.810M
US$ 0.10
0.00 0.00
0
17.21M
US$ 1.800M
US$ 3.00
0.25 9.09
288,674
559,444
US$ 1.680M
C$ 0.005
0.00 0.00
0
283.28M
C$ 1.420M
US$ 0.09
0.00 0.00
0
16.39M
US$ 1.390M
C$ 0.09
0.00 0.00
75,000
13.86M
C$ 1.250M
US$ 2.01
0.29 16.86
198,430
578,625
US$ 1.160M
US$ 0.30
0.00 0.00
0
3.78M
US$ 1.130M
US$ 0.14
-0.0034 -2.37
740
8.10M
US$ 1.130M
US$ 0.20
0.00 0.00
0
4.44M
US$ 894K
US$ 0.11
0.00 0.00
0
6.58M
US$ 705K
US$ 0.06
-0.0015 -2.44
4,072
11.62M
US$ 697K
US$ 0.02
0.00 0.00
0
29.49M
US$ 678K
US$ 0.001
-0.0003 -23.08
254,818
635.87M
US$ 636K
US$ 0.07
0.00 0.00
50
8.31M
US$ 607K
US$ 0.25
0.00 0.00
0
1.63M
US$ 413K
US$ 0.21
0.00 0.00
0
1.55M
US$ 326K
US$ 0.008
0.00 0.00
0
39.74M
US$ 318K
US$ 0.07
0.00 0.00
0
4.44M
US$ 289K
US$ 0.004
0.00 0.00
0
61.76M
US$ 247K
US$ 0.001
0.00 0.00
0
232.37M
US$ 232K
US$ 0.37
0.00 0.00
0
581,000
US$ 215K
US$ 0.16
0.00 0.00
0
1.33M
US$ 206K
US$ 0.02
0.00 0.00
0
4.85M
US$ 97K
US$ 0.005
0.00 0.00
0
5.23M
US$ 26K
US$ 0.02
0.00 0.00
0
1.24M
US$ 26K
US$ 0.01
0.00 0.00
0
863,788
US$ 10K
US$ 0.07
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
4.87M
US$ -
US$ 1.06
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 3.01
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 32.95
0.00 0.00
0
-
US$ -
US$ 1.20
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
1.39M
US$ -
US$ 0.00
0.00 0.00
0
125.63M
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 0.02
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
5.12B
US$ -
US$ 0.02
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
261.79M
US$ -
US$ 2.14
0.16 8.08
194,902
-
US$ -
C$ 3.35
0.00 0.00
0
-
C$ -
US$ 1.81
0.03 1.69
246,228
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest Biotechnology Stock News


Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual...

New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes Eight abstracts, including four late-breaking abstracts, underscore Jazz's continued commitment to the epilepsy community and advancing the comprehensive treatment for rare forms of epilepsy DUBLIN, Dec. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced... Read more


Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

AMX0114 was generally well-tolerated, with no treatment-related serious adverse events Amylyx will proceed with opening enrollment of second cohort Data are being presented at the 36th International Symposium on ALS/MND CAMBRIDGE, Mass. / Dec 05, 2025 / Business Wire / Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the presentation of early safety and tolerability data from its Phase 1 LUMINA trial of AMX0114 and results... Read more


Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy...

Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life Propensity score weighted analysis comparing the effects of zorevunersen to natural history showed reductions in seizures and improvements in cognition and behavior with dose levels and timepoints... Read more


Xenon Pharmaceuticals Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure freedom New X-TOLE OLE data analysis supports the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalner, even in patients with difficult-to-treat disease Four real-world study posters illustrate significant burden of depression and ASM titration on people living with epilepsy; poster... Read more


XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology

EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced acquisition of the entire issued and to be issued share capital of Mural Oncology plc (“Mural”) (Nasdaq: MURA) (the “Acquisition”) pursuant to an Irish High Court sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014... Read more


Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients’ disease severity  RAP-219 demonstrated meaningful improvements in patient-reported seizure severity among those with moderate or greater baseline impairment BOSTON and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (Rapport... Read more


Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC

BOSTON, Dec. 5, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced it has been awarded by the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory (PNNL) a four-year, up to $47M contract to co-design, build, and integrate a High‑Throughput Automated Phenotyping Platform (HTP‑APP) in support of the Microbial Molecular Phenotyping Capability (M2PC). The platform, selected through a competitive procurement process,... Read more


CG Oncology: New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer

Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort P CORE-008 Cohort A Data in HR BCG-Naïve NMIBC demonstrates 88% CR and favorable safety with optimized administration Robust clinical pipeline that spans multiple late-stage studies across intermediate- and high-risk NMIBC IRVINE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical... Read more


Lexicon Pharmaceuticals: Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum (CVCT 2025). The conference is being held December 8-10, 2025, at the Mayflower Hotel in Washington, D.C. This data is from SOTA-P-CARDIA, a prospective, randomized, double-blind, placeb... Read more


OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility

U.S. FDA grants waiver of application fee for BLA Filing of OST-HER2 Scheduled pre-Marketing Authorisation Application meeting with United Kingdom's Medicines and Healthcare products Regulatory Agency on December 8, 2025 Scheduled Type C Meeting with United States Food & Drug Administration on December 11, 2025 New York, New York--(Newsfile Corp. - December 5, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader... Read more


INmune Bio: Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform

Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage inflammation and immunology company, announces a recently published overview of future applications and research areas for mesenchymal stromal cell (MSC) therapies, such as INmune’s CORDStrom™ platform. The article, titled, “Fate and Function of Exogenously Administered MSCs: Current Insights and Future Directions,” was published... Read more


Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 Diabetes SAN CARLOS, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it presented COVALENT-111 study results at the 23rd WCIRDC which took place December 3-6, 2025 in Los Angeles, California. The data showed durable glycemic... Read more


Immatics Announces $125 Million Underwritten Offering

Houston, Texas and Tuebingen, Germany, December 05, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, announced today that it has agreed to sell 12,500,000 ordinary shares at $10.00 per share in an underwritten offering. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be $125... Read more


ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases Manageable safety profile with low discontinuation rate Enrollment completed; no further development planned in this patient population Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology... Read more


ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO...

Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain metastases 36% ORR in median 3L EGFR PACC patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate Enrollment and follow-up continue in 1L EGFR PACC patients at selected dose of 80 mg once daily, with next... Read more


Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct... Read more


CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology Significant reduction in key neurodegeneration biomarker correlated with treatment response, suggesting neflamapimod may act on underlying disease CervoMed preparing to initiate Phase 3 registrational trial in patients with DLB in the second half of 2026 BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Today in a late-breaking... Read more


Vanda Pharmaceuticals: FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness

WASHINGTON, Dec. 4, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on protocol VP-VLY-686-3403, which until today limited the protocol to a maximum of 90 doses of tradipitant. The lift followed Vanda's formal dispute resolution request and an expedited re-review conducted by CDER leadership under the collaborative framework established between Vanda and... Read more


Protara Therapeutics Announces Proposed Public Offering

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has commenced an underwritten public offering of $75 million in aggregate of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares... Read more


Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming meeting with the FDA to discuss the results and NDA path BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous... Read more


OmniAb to Hold OmniUltra Virtual Investor Event on December 15

EMERYVILLE, Calif. / Dec 04, 2025 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced it will hold a virtual investor event to showcase the launch of OmniUltra™ on Monday, December 15, 2025, beginning at 5:00 p.m. Eastern time. The event is expected to last approximately one hour and will include a review of OmniAb’s newest technology offering, OmniUltra, the industry's only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody... Read more


Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026 BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the successful completion of its pre-NDA (New Drug Application)... Read more


Kala Bio Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.00 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering... Read more


Oncotelic Therapeutics and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine

AGOURA HILLS, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano today announced new biomarker data identifying a molecular signature that predicts sensitivity to Sapu003, the company’s intravenous Deciparticle™ formulation of everolimus. These data will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) Dec 9-12. This work describes the first prospective biomarker framework... Read more


Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations

Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), a leader in autologous stem cell therapeutics for ischemic diseases, is pleased to announce the appointment of Shaune Harding, OStJ, RN non-practicing, as Director of Patient Care & Clinical Operations. In this senior clinical role, Ms. Harding will oversee: On-boarding of all new patients entering Hemostemix treatment p... Read more


BioAge Labs Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a cytokine directly downstream of NLRP3, at Day 14 High brain penetration: BGE-102 doses of 60 mg and higher exceeded target IC90 levels in cerebrospinal fluid (CSF) at Day 14 Company is expanding the Phase 1 trial to include MAD cohorts in participants with obesity and elevated... Read more


Alpha Tau Medical Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium

Pancreatic cancer multi-center clinical trial in U.S. is underway; patient recruitment expected to be completed by the end of Q1 2026 JERUSALEM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that two abstracts have been accepted to the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal... Read more


Devonian Health Announces Publication of Landmark Study Highlighting Thykamine™ as a Promising New Anti-Inflammatory Agent

QUÉBEC, Dec. 4, 2025 /CNW/ - Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical corporation specializing in the development of prescription drugs targeting fibroinflammatory diseases, is pleased to announce the publication of a peer-reviewed article in Biomedicines titled "Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs." The study presents notable evidence supporting the potent multi-target... Read more


Senti Biosciences to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00...

SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced it will host a conference call and webcast to discuss updated clinical results from SENTI-202 being presented at the ASH Annual Meeting on Tuesday, December 9, 2025 at 8:00 AM ET. The call will be... Read more


Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAE LYMPHIR international availability extends to 19 markets outside the U.S. CRANFORD, N.J., Dec. 4, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has entered into... Read more


Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium

IRVING, Texas, Dec. 4, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading cancer centers, including those within the Caris Precision Oncology Alliance ™ (Caris POA), will collectively present 19 studies across a range of breast cancer types at the San Antonio Breast Cancer Symposium (SABCS)... Read more


Galmed Pharmaceuticals Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (USPTO), Europe, Canada and other jurisdictions and will expire in the U.S. in July 2042. Aramchol is a first-in-class, Phase 3 ready, drug candidate, that showed robust fibrosis improvement in advanced clinical studies.  Aramchol's excellent safety and tolerability is a perfect drug candidate to be combined with other MASH drugs, approved... Read more


Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 (“NK-1”) antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker onset than oral aprepitant Aprepitant alone, or added to a multimodal regimen, recognized as significantly reducing the risk of PONV, and aprepitant monotherapies are noted as more effective compared to 5-HT3 receptor antagonists for postoperative vomiting prevention... Read more


Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia

Study to evaluate safety and efficacy of novel anti-PRLR antibody; interim data anticipated in the second half of 2026 Trial design leverages operational synergies to enable accelerated registrational trials for androgenetic alopecia (AGA) and Phase 2 for endometriosis KOL seminar scheduled for December 11 to discuss new human ex vivo data, clinical trial design, and market opportunity in AGA VANCOUVER, Wash. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Absci... Read more


Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum

Company positioned to pursue expedited regulatory pathways in metastatic, neoadjuvant, and risk-reduction settings SEATTLE, Dec. 4, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming breast cancer treatment and prevention, announced the completion of a Type C meeting with the U.S. Food and Drug Administration ("FDA") on November 17, 2025, to review regulatory... Read more


Estrella Immunopharma Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

An independent Data Safety Monitoring Board (DSMB) confirms EB103’s favorable safety profile with no treatment-related serious adverse events (SAEs) even in high-risk patients who are ineligible for currently available commercial CD19 products DSMB recommends advancement of STARLIGHT-1 to Phase II at the Recommended Phase II Dose (RP2D) High-dose cohort of Phase I achieved a 100% complete response (CR) rate at Month 1 Data supports EB103’s potential as a best-in-class... Read more


Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

Management to meet with investors and potential partners during Biotech Showcase 2026 CAMBRIDGE, Mass. / Dec 04, 2025 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company will present and participate in the Sachs Associates 9th Annual Neuroscience Innovation Forum... Read more


Enlivex Therapeutics Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development

Nes-Ziona, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), today announced that it will host a virtual fireside chat on Thursday, December 11, 2025 at 11:00 am ET. Shai Novik, Executive Chairman of Enlivex, will provide an update on the Company’s plans following its recently closed $212,000,000 private placement. Mr. Novik will discuss the launch of Enlivex’s digital asset treasury strategy built... Read more


Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced plans to host a virtual event, “A Clinician’s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy,” at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum on Tuesday, December 9th at 3 PM ET. The session will... Read more


Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

SHELTON, Conn., Dec. 4, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, today announces two presentations at the upcoming 2025 San Antonio Breast Cancer Symposium... Read more


NeuroSense Therapeutics to Hold Pre-NDS Meeting with Health Canada in April 2026

CAMBRIDGE, Mass., Dec. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that following a productive discussion with Health Canada ("Agency"), the Company is resuming its regulatory advancement in Canada for PrimeC in amyotrophic lateral sclerosis (ALS). After outlining the remaining requirements,... Read more


Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent GBM demonstrated promising safety and efficacy signal, supporting continued Phase 2 enrollment and investigation MRI combined with SPECT imaging biomarkers effectively evaluate overall survival response with REYOBIQ in recurrent GBM treatment and help guide personalized patient... Read more


Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment of 15 months Company to accelerate development of PLN-101095 with initiation of a Phase 1b expansion trial in 2026 Strong cash position supports planned operations through 2028 SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics,... Read more


Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa. Tividenofusp alfa is Denali’s lead investigational TransportVehicleTM-enabled enzyme replacement therapy for the treatment of mucopolysaccharidosis type II (MPS II, or Hunter syndrome). A Biologics License... Read more


uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

LEXINGTON, Mass. and AMSTERDAM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company received final meeting minutes from the U.S. Food and Drug Administration (FDA) regarding a pre-Biologics License Application (BLA) meeting held on October 29, 2025 to discuss the application for AMT-130, an investigational gene therapy for... Read more


PreveCeutical Medical Announces Grant of Patent for Innovative Pain Therapy Technology

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical")  is pleased to announce that the Australian Patent Office has granted Australian Patent No. AU2020212659, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This patent represents a significant milestone in the development and protection of PreveCeutical's proprietary... Read more


Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa. Tividenofusp alfa is Denali’s lead investigational TransportVehicle™-enabled enzyme replacement therapy for the treatment of mucopolysaccharidosis type II (MPS II, or Hunter syndrome). A Biologics License... Read more


SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery

PRAGUE, Czech Republic and DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- SCTbio, a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea, a leading global contract research organization (CRO), today announced a strategic collaboration agreement between the two companies. This partnership aims to streamline development, accelerate timelines and bring advanced therapies to patients faster. This collaboration represents a forward-looking... Read more


MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026 Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer’s disease psychosis expected in the second half of 2027 Raised $296.5 million in gross proceeds from initial public offering and concurrent private placement completed in October 2025 Cash, cash equivalents and short-term investments sufficient to fund operations through 2027 SAN FRANCISCO... Read more


Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it will present new preclinical data from... Read more